The enriched pathways of Hsa-miR-26a-1-3p were “Prion diseases,” “p53 signalling pathway” and “Non-small-cell lung cancer.” The enriched pathways of hsa-miR-7-2-3p were “Cytokine-cytokine receptor interaction,” “Pathways in cancer” and “Small-cell lung cancer.” The putative targets of both miRNAs can be seen in Supplementary Table 1. This evidence concerns the gene TP53 and prion disease.